PD57-08 TUMORAL CD8+ T CELLS CORRELATE WITH FAVORABLE OUTCOME IN METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) III1 Apr 2018PD57-08 TUMORAL CD8+ T CELLS CORRELATE WITH FAVORABLE OUTCOME IN METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS Jiajun Wang, Li Liu, Wei Xi, Jiejie Xu, and Jianming Guo Jiajun WangJiajun Wang More articles by this author , Li LiuLi Liu More articles by this author , Wei XiWei Xi More articles by this author , Jiejie XuJiejie Xu More articles by this author , and Jianming GuoJianming Guo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2652AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES CD8+ T cells play a central role in cancer immune elimination, and tyrosine kinase inhibitor (TKI) therapy could enhance their anti-tumor function. We aim to investigate the predictive value of CD8+ T cells for TKI therapy in metastatic renal cell carcinoma (mRCC) patients. METHODS One hundred and thirty-eight metastatic mRCC patients treated with TKIs were retrospectively scanned, and 111 eligible patients were finally enrolled. CD8+ T cell density and major histocompatibility complex (MHC) class I expression in tumor tissues was assessed by immunohistochemistry. Associations between CD8+ T cell density, MHC class I expression and local immune cytolytic activity were also assessed in the TCGA cohort. RESULTS CD8+ T cells were observed in mRCC samples (median density 45 cells/mm2, range 0-2750 cells/mm2). Patients with high density of CD8+ T cells showed higher response rate (P=0.002), longer overall survival (OS) (hazard ratio=0.510, P=0.005) and longer progression-free survival (PFS) (hazard ratio=0.591, P=0.012) under TKI therapy. Multivariate Cox analyses identified high CD8+ T cell density as an independent prognostic factor for both OS (hazard ratio=0.559, P=0.027) and PFS (hazard ratio=0.574, P=0.017). We also identified close relationship between high CD8+ T cell infiltration, activated antigen presentation mechanism and enhanced immune cytolytic activity. Moreover, mRCC patients with both high tumoral CD8+ T cell density and high MHC class I expression showed significantly prolonged survival (P<10-4). CONCLUSIONS Tumoral CD8+ T cell density could serve as a predictive marker for TKI therapy in mRCC patients, especially in those with high MHC class I expression. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1069-e1070 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jiajun Wang More articles by this author Li Liu More articles by this author Wei Xi More articles by this author Jiejie Xu More articles by this author Jianming Guo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...